MRPL9

Across TCGA pan-cancer cohorts, MRPL9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRPL9 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MRPL9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL9 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where MRPL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.238	0.468	.013	5	view →
LSCC	OS	Median	II,III,IV	1.000	0.882	.020	2	view →
HNSC	OS	Quartile	IV	0.689	0.930	.008	2	view →
LUAD	DFS	Median	III,IV	0.722	0.285	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRPL9–PDAC (DFS)

Open the PDAC breakdown →